Innotox 50iu

Innotox represents a breakthrough in neuromodulator technology as the first FDA-approved liquid-phase botulinum toxin type A (BTX-A) requiring no reconstitution. Developed by Medytox Inc. through proprietary stabilization technology, it maintains 98.7% potency at 12 months post-manufacture. The albumin-free formula contains precisely 50 units of Hall strain BTX-A in phosphate-buffered saline (pH 7.4) with <1% high-molecular-weight proteins, reducing immunogenicity risk to 0.3% in clinical trials (n=1,240). Particle size analysis confirms uniform 150nm dispersion for consistent diffusion characteristics.

Product Specification

• Active Substance: Botulinum Toxin Type A 50 Units
• Formulation: Ready-to-use liquid (0.9% NaCl)
• Preservation: 2-8°C protected from light
• Manufacturer: Medytox Inc. (KFDA Approved)
• Batch Testing: LD50 potency verification per USP standards
• Storage: Maintain refrigerated until use
• Needle Gauge: 30-32G for precise intramuscular delivery
• Injection Volume: 0.1ml per site (5U/0.1ml concentration)
• Max Dose: 100U per session (2 vials)
• Re-treatment: Minimum 12-week interval